MRK vs TEVA
Merck & Co. vs Teva Pharmaceutical Industries Limited — AI-powered side-by-side comparison
VS
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
| Metric | MRK | TEVA |
|---|
| AI Score |
70
|
55
|
| Price |
$130.34
|
$36.49
|
| P/E Ratio |
103.53×
|
57.19×
|
| ROE |
34.7%
|
17.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
52.5%
|
| Debt / Equity |
1.29×
|
2.16×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
77.8
|
| Beta |
0.207
|
0.864
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus TEVA.
MRK leads by 15 points.
MRK scores 70/100 (Buy) versus TEVA at 55/100 (Watch).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TEVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 57.5 is expensive by classic value standards — Value
- Price-to-book of 4.9x prices in significant intangible value — Value
- Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value